The bankrupt health system did not receive any qualified bidders in Ohio and Pennsylvania.
Steward fails to spark competitive auction during first round of hospital sales Read More »
The device is designed to perform the most commonly ordered blood tests, avoiding the need to send the samples to central labs.
Truvian raises $74M to bring blood test instrument to market Read More »
Two years after Embecta spun out of BD, the firm is now exploring a potential sale, the Financial Times reported.
Diabetes device firm Embecta considers sale: Financial Times Read More »
The take-private deal would help the firm scale its documentation products to more providers and health systems, CEO Manny Krakaris said.
Commure to acquire AI scribe Augmedix in $139M deal Read More »
One warning letter covers the production of plastic syringes for Cardinal Health.
FDA sends 2 warning letters after inspecting Chinese syringe manufacturers Read More »
Stacey Churchwell, who leads the company’s cardiovascular diagnostics and services business, says artificial intelligence is reducing false positives in its insertable cardiac monitors, saving clinicians valuable time.
‘Our next frontier is prediction’: Medtronic on AI and heart disease Read More »
Agents and brokers connecting consumers with Affordable Care Act plans now have to jump new hurdles to change their coverage, following mounting complaints about unauthorized plan switching.
CMS cracks down on ACA brokers to prevent plan switching Read More »
The three payers were cut out of the state’s first round of contracts divvied out in April.
Florida awards additional Medicaid contracts to CVS, UnitedHealth, Molina Read More »
The South Korean company’s Epysqli is now FDA-approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in the U.S., having grabbed the lead in the Soliris biosimilar market in Europe.
Samsung Bioepis Gets FDA Approval for Biosimilar to AstraZeneca’s Soliris Read More »
Innovent Biologics’ dual GLP-1/glucagon receptor agonist mazdutide is also being developed for chronic weight management. China’s regulator accepted Innovent’s drug application for this indication in February 2024.
